SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Emily Dickinson

PatientEmily Dickinson
Date of birth1971-12-10
IdentifiersMRN HR-NI023-SYN; SSN (made up) 000-23-6081
Document date2026-03-02
AuthorLucinda Hartwell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Video visit four weeks after the losartan increase and dapagliflozin start. [S]

History of Present Illness

Ms. Dickinson is seen by video from her home. The mobile phlebotomy service drew her blood this morning. Before the call she measured her blood pressure twice with her validated upper-arm cuff after five minutes' rest, and her weight, temperature, and oxygen saturation with her own devices; Dr. Hartwell counted her breathing on video. She has taken losartan 100 mg and dapagliflozin 10 mg daily for four weeks. She has had a headache only once in the past two weeks. She passes a little more urine and has had no lightheadedness, genital itching, or urinary symptoms. Her home blood pressure averages 138/84 over the past two weeks. She drinks to thirst, about 1.5 L a day. [S]

ElementDetail
Visit formatVideo visit from home, with home-measured vital signs and a home blood draw this morning
HeadachesOnce in two weeks
Medication toleranceNo lightheadedness, genital itching, or urinary symptoms on dapagliflozin
Home blood pressureAverage 138/84 mmHg over two weeks
FluidsAbout 1.5 L a day, to thirst

Review of Systems

SystemResultFinding
NeurologicalNegativeOne mild headache in two weeks; no lightheadedness
GenitourinaryNegativeSlightly more urine; no dysuria, itching, or discharge
CardiovascularNegativeNo palpitations or ankle swelling

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter)Two tablets as needed, up to twice a dayOral route2025-10-01 to 2026-01-12stoppedS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12 to 2026-02-02completedS
Losartan 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-02-02activeS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12activeS
Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-01-12activeS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a dayTwo tablets every 6 hours as needed; maximum 6 tablets a dayOral route2026-01-12activeS
Dapagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-02-02activeS
Amlodipine 5 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route2026-03-02activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-03-02Body height163cmS
2026-03-02Body weight53.6kgS
2026-03-02Body mass index (BMI) [Ratio]20.2kg/m2S
2026-03-02Systolic blood pressure136mm[Hg]S
2026-03-02Diastolic blood pressure84mm[Hg]S
2026-03-02Heart rate72/minS
2026-03-02Respiratory rate14/minS
2026-03-02Body temperature36.6CelS
2026-03-02Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-03-02Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
2026-03-02Potassium [Moles/volume] in Serum or Plasma4.8mmol/L3.5-5.1 mmol/LNormalS
2026-03-02Carbon dioxide, total [Moles/volume] in Serum or Plasma23mmol/L22-29 mmol/LNormalS
2026-03-02Urea nitrogen [Mass/volume] in Serum or Plasma23mg/dL6-21 mg/dLHighS
2026-03-02Creatinine [Mass/volume] in Serum or Plasma1.32mg/dL0.59-1.04 mg/dLHighS
2026-03-02Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M48mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
2026-03-02Glucose [Mass/volume] in Serum or Plasma88mg/dL70-99 mg/dLNormalS

Physical Exam

Vital signs recorded on 2026-03-02; see the Vital Signs section. [S]

SystemFinding
General (video)Comfortable and well groomed; speaking in full sentences; respiratory rate 14 counted on video
Extremities (video)She pressed on both shins for five seconds: no pitting seen
Mental status (video)Alert, engaged, and dryly humorous; mood "steadier"

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificateactiveconfirmed N18.31S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists.
Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertensionactiveconfirmed I12.9S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists.
Vitamin D deficiency with a mildly raised PTH in chronic kidney diseaseactiveconfirmed E55.9S — Synthetic laboratory finding at the intake visit.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPotassium and creatinine after increasing the ARB and starting the SGLT2 inhibitor2 to 4 weeks after starting or increasing an ACE inhibitor, ARB, SGLT2 inhibitor, or MRACompleted todayPotassium 4.8 mmol/L, creatinine 1.32 mg/dL, eGFR 48, four weeks after both changes
ExaminationStandardized home blood pressure on a validated cuffEvery visitCompleted today136/84 mmHg today; two-week home average 138/84
ExaminationWeightEvery visitCompleted today53.6 kg on her home scale
ExaminationCardiac auscultationEvery visitDeferredNot possible at a video visit; no new cardiac symptoms. It was done three weeks after intake at the clinic visit and will be done at the home visit in June
Medication safetySGLT2 inhibitor safety: volume status and genital infectionAt each review after startingCompleted todayNo lightheadedness or genital symptoms; fluids to thirst
Medication safetyMedication review: NSAID avoidance and dose adjustmentEvery visitCompleted todayNo NSAIDs; acetaminophen once in two weeks
LaboratoryPotassium and creatinine after starting amlodipineNot required for a calcium-channel blockerNot indicatedAmlodipine does not affect potassium or creatinine; the next panel is at the three-month review
LaboratoryeGFR and urine albumin-creatinine ratioTwice a year at G3a A2 (KDIGO heat map)DueNext at the three-month review to judge the albuminuria response
Self-managementSick-day rulesAt each start of a RAAS blocker or SGLT2 inhibitor, and yearlyCompleted todayReviewed again by video

Goal progress:

Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026)

Follow-up: Home visit in three months with blood and urine tests; weekly home blood pressure readings by message. Next scheduled visit 2026-06-01: home visit for the three-month kidney and blood pressure review. [S]